NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Diagnostics & Research · CAD

Spectral Medical Inc. (EDT.TO) Stock Analysis

Spectral Medical Inc. (EDT.TO) is a Diagnostics & Research stock listed on TSX and quoted in Canadian Dollar.

EDT.TO

CA$1.26

−CA$0.03 (−2.33%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EDT.TO with… →

EDT.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$1.26
Previous Close
CA$1.29
Day's Range
1.26–1.28
52-Week Range
1.21–1.76
Volume
15.06K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.18
Valuation
Market Cap
CA$369.88M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
63.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
143.98
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.12
Financials (FY)
Revenue (FY)
CA$2.44M+6.82%
Net Income (FY)
−CA$47.69M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
293.55M
1-Year Return
−20.75%
Dividend and dates
Earnings Date
November 6, 2026estimated
Avg Volume
51.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EDT.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.50%
2025+188.00%
2024+17.65%
2023+14.86%
2022+68.18%
2021−45.68%
2020−43.75%
2019+152.63%
2018−25.00%
2017+38.18%
2016 (partial year)−77.27%

As of September 4, 2026.

EDT.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$2.44M−CA$47.69M−1953.0%
2024CA$2.29M−CA$15.40M−673.8%
2023CA$1.60M−CA$15.66M−980.1%
2022CA$1.67M−CA$11.28M−676.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$2.44MCA$1.33M−CA$11.69M−CA$47.69M−1953.0%
2024CA$2.29MCA$713.00K−CA$12.00M−CA$15.40M−673.8%
2023CA$1.60MCA$662.00K−CA$8.45M−CA$15.66M−980.1%
2022CA$1.67MCA$983.00K−CA$6.05M−CA$11.28M−676.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EDT.TO Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricEDT.TODiagnostics & Research medianvs median
P/S ratio143.984.9928.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Spectral Medical Inc. (EDT.TO) is capitalised at CA$369.88M on the latest close. The company sits in the Healthcare sector, in the Diagnostics & Research industry. Headcount on file is 29.

The most recent close on file for EDT.TO is CA$1.26, dated September 4, 2026. That is −CA$0.03 (−2.33%) against the previous close. The 52-week range on file runs from CA$1.21 to CA$1.76. The latest close sits 4.13% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$2.44M. Against the prior fiscal year total of CA$2.29M, that is a change of +6.82%. The same year closed with a net loss of CA$47.69M. The reported profit margin is 0%. Trailing earnings per share are −0.12.

Across the 4 fiscal years on file, revenue moves from CA$1.67M in 2022 to CA$2.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 63. Measured against sales, the shares trade at 143.98 times revenue. On price-to-sales that is 28.9 times the Diagnostics & Research median of 4.99. The medians here are taken across 49 Diagnostics & Research companies that report the metric.

Over the trailing twelve months the price has returned −20.75%. Measured over 10 years, that is +1.09% a year compounded. Beta against the wider market is reported at 0.18. Daily returns over the trailing 10 years annualize to a volatility of 76.68%.

Growth & Income

The record shows no dividend for EDT.TO.

2026 is still running; the price is −12.50% year to date. The strongest complete calendar year on file is 2025 at +188.00%; the weakest is 2021 at −45.68%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Spectral Medical Inc. (EDT.TO) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Spectral Medical Inc. EDT.TO CA$369.88M —
Thermo Fisher Scientific Inc. TMO CA$226.94B 33.0
Danaher Corporation DHR CA$145.98B 37.0
Natera, Inc. NTRA CA$47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Spectral Medical Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Spectral Medical Inc.

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Visit website →